Traynor Capital Management Inc. Purchases New Shares in Stereotaxis, Inc. (NYSEAMERICAN:STXS)

Traynor Capital Management Inc. bought a new stake in Stereotaxis, Inc. (NYSEAMERICAN:STXS) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 160,509 shares of the company’s stock, valued at approximately $366,000.

A number of other large investors have also recently added to or reduced their stakes in STXS. SG Americas Securities LLC acquired a new position in Stereotaxis in the third quarter valued at approximately $39,000. Jane Street Group LLC lifted its stake in Stereotaxis by 26.9% in the third quarter. Jane Street Group LLC now owns 29,773 shares of the company’s stock valued at $61,000 after buying an additional 6,313 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Stereotaxis by 645.6% during the second quarter. Rhumbline Advisers now owns 48,251 shares of the company’s stock valued at $88,000 after acquiring an additional 41,780 shares during the period. Barclays PLC grew its position in shares of Stereotaxis by 449.9% during the third quarter. Barclays PLC now owns 101,953 shares of the company’s stock worth $208,000 after acquiring an additional 83,412 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Stereotaxis by 10.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 167,297 shares of the company’s stock worth $341,000 after acquiring an additional 15,491 shares during the period. 45.35% of the stock is currently owned by institutional investors.

Stereotaxis Price Performance

Stereotaxis stock opened at $2.21 on Friday. Stereotaxis, Inc. has a 52-week low of $1.66 and a 52-week high of $3.29.

Stereotaxis (NYSEAMERICAN:STXS) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The business had revenue of $9.20 million during the quarter, compared to the consensus estimate of $6.80 million. Stereotaxis had a negative return on equity of 162.54% and a negative net margin of 85.79%. Equities analysts forecast that Stereotaxis, Inc. will post -0.26 EPS for the current fiscal year.

Stereotaxis Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.